BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23456506)

  • 1. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.
    Hyeon J; Ahn S; Lee JJ; Song DH; Park CK
    Dig Dis Sci; 2013 Jul; 58(7):1916-22. PubMed ID: 23456506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.
    Lee B; Ha SY; Song DH; Lee HW; Cho SY; Park CK
    Gut Liver; 2014 Nov; 8(6):662-8. PubMed ID: 25368754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
    Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
    Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
    Ha SY; Song DH; Lee JJ; Lee HW; Cho SY; Park CK
    Gut Liver; 2014 Nov; 8(6):648-54. PubMed ID: 25287169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy.
    Kim SH; Ahn S; Park CK
    Hepatobiliary Pancreat Dis Int; 2012 Feb; 11(1):51-9. PubMed ID: 22251470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma.
    Nakanishi K; Sakamoto M; Yamasaki S; Todo S; Hirohashi S
    Cancer; 2005 Jan; 103(2):307-12. PubMed ID: 15593087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion.
    Kim JM; Kwon CH; Joh JW; Ko JS; Park JB; Lee JH; Kim SJ; Paik SW; Park CK
    World J Surg Oncol; 2013 Apr; 11():92. PubMed ID: 23618082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
    Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
    BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma.
    Ahn S; Hyeon J; Park CK
    Hepatobiliary Pancreat Dis Int; 2013 Jun; 12(3):286-94. PubMed ID: 23742774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
    Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection.
    Ding X; Wang K; Wang H; Zhang G; Liu Y; Yang Q; Chen W; Hu S
    J Gastrointest Surg; 2012 Apr; 16(4):828-36. PubMed ID: 22072303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis.
    Ha SY; Kim JH; Yang JW; Kim J; Kim B; Park CK
    Cancer Res Treat; 2016 Jul; 48(3):1065-73. PubMed ID: 26511806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of prothymosin alpha predicts early recurrence and poor prognosis of hepatocellular carcinoma.
    Ha SY; Song DH; Hwang SH; Cho SY; Park CK
    Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):171-7. PubMed ID: 25865690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma.
    Kamiyama T; Nakanishi K; Yokoo H; Kamachi H; Tahara M; Kakisaka T; Tsuruga Y; Todo S; Taketomi A
    World J Surg Oncol; 2012 Jun; 10():107. PubMed ID: 22697061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of β1,6-N-acetylglucosaminyltransferase V expression in patients with hepatocellular carcinoma.
    Liu H; Wu Q; Liu Y; Liu W; Zhang W; Pan D; Xu J
    Jpn J Clin Oncol; 2015 Sep; 45(9):844-53. PubMed ID: 26056329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection.
    Fu YP; Yi Y; Cai XY; Sun J; Ni XC; He HW; Wang JX; Lu ZF; Huang JL; Cao Y; Zhou J; Fan J; Qiu SJ
    Br J Cancer; 2016 Mar; 114(7):767-76. PubMed ID: 27002937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-operative predictors of early recurrence/mortality including the role of inflammatory indices in patients undergoing partial hepatectomy for spontaneously ruptured hepatocellular carcinoma.
    Chua DW; Koh YX; Liew YX; Chan CY; Lee SY; Cheow PC; Chow PK; Chung AY; Ooi LL; Goh BK
    J Surg Oncol; 2018 Dec; 118(8):1227-1236. PubMed ID: 30399204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection.
    Zhu W; Guo L; Zhang B; Lou L; Lin Z; Zhu X; Ren N; Dong Q; Ye Q; Qin L
    Ann Surg Oncol; 2014 Apr; 21(4):1304-13. PubMed ID: 24366422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma.
    Poon RT; Fan ST; Ng IO; Lo CM; Liu CL; Wong J
    Cancer; 2000 Aug; 89(3):500-7. PubMed ID: 10931448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy.
    Zheng H; Yang Y; Wang MC; Yuan SX; Tian T; Han J; Ni JS; Wang J; Xing H; Zhou WP
    Surg Oncol; 2016 Sep; 25(3):171-7. PubMed ID: 27566019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.